MedTrace Logo

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

NCT05840835 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-08-08

No results posted yet for this study

Summary

Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab. The recommended Phase 2 dose (RP2D) will be evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1 protocol during the conduct of the Phase 1 study.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

IMX-110 combined with Tislelizumab

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Sponsors & Collaborators

  • BeiGene

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Immix Biopharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-03
Primary Completion
2024-01-24
Completion
2024-01-24
FDA Drug
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05840835 on ClinicalTrials.gov